Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
GPIIb/IIIa Receptor Antagonist (Cyclic Peptide)

Eptifibatide (GPIIb/IIIa Inhibitor — ACS/PCI)

Brand names: Integrilin

Eptifibatide is an intravenous glycoprotein IIb/IIIa receptor antagonist used as an antiplatelet agent in acute coronary syndromes and during percutaneous coronary intervention.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It reversibly blocks the platelet glycoprotein IIb/IIIa receptor, preventing fibrinogen binding and the final common pathway of platelet aggregation.

Prescribing in practice

  • Major bleeding and thrombocytopenia are the principal risks, so it is contraindicated with active bleeding and recent haemorrhagic stroke.
  • Dosing requires adjustment in renal impairment because clearance is partly renal.
  • It is used with aspirin and an anticoagulant, increasing overall bleeding risk that must be balanced against ischaemic benefit.

Monitoring

Monitor platelet count and for bleeding during and after the infusion, and assess renal function.

Counselling the patient

  • This is an intravenous antiplatelet medicine used during treatment of a heart attack or stent procedure.
  • Report any bleeding, bruising or blood in the urine or stool.
  • The team will check your blood counts during treatment.

Evidence & guidelines

The PURSUIT and ESPRIT trials supported eptifibatide use in acute coronary syndromes and percutaneous coronary intervention.

Reference: PURSUIT Trial (NEJM 1998); ESPRIT Trial (NEJM 2001); ESC PCI Guidelines 2023; MHRA SPC Integrilin; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways